Race Oncology Ltd has released a press release.
EMD AML MDS Trial Expands to Europe
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Zantrene AML trial in Israel advances to Phase 2
- Race Receives Governance Approval for AML EMD & MDS Trial
- Race receives Human Ethics AML Trial Approval
- Supply Agreement for EMD AML Trial
- Zantrene highly effective in EMD AML Mouse Model
Later from Racura Oncology
- Race Oncology Announces On-Market Share Buyback
- Zantrene Improves Immune Therapy Treatment of Melanoma
- Zantrene shows synergy with kinase inhibitors in melanoma
- Zantrene Protects Mouse Hearts from Chemotherapy Damage
- Race Oncology: Quarterly Activity Report & Appendix 4C
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology